Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, MD, Kenneth D Friedman, MD, Sweta Gupta, MD, Kristina M. Haley, DO, Chunla He, Salley Pels, MD, Jonathan C. Roberts, MD, Crystal Watson, BS, Robert F. Sidonio, Jr., MD MSc.

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-137124

Published: 2020

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Courtney D Thornburg, MD, Kenneth D Friedman, MD, Michael F Guerrera, MD, Chunla He, Lynn M Malec, MD, Mindy L Simpson, MD, Michael D Tarantino, MD, H. Marijke Van Den Berg, Crystal Watson, BS, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138748

Published: 2020

Journal Articles

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Pamela A Christopherson, Rupa A Udani, PhD, Crystal Perry, BS, Daniel B Bellissimo, PhD, Sandra L Haberichter, PhD, Veronica H Flood, MD, Kenneth D Friedman, MD, Joan Cox Gill, MD, Robert R. Montgomery, MD, Zimmerman Program Investigators

Blood (2016) 128 (22): 872.

https://doi.org/10.1182/blood.V128.22.872.872

Published: 2016

Journal Articles

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Sandra L Haberichter, PhD, Pamela A Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Kenneth D Friedman, MD, Robert R. Montgomery, MD

Blood (2016) 128 (22): 874.

https://doi.org/10.1182/blood.V128.22.874.874

Published: 2016

Journal Articles

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Kevin Pirelli, BS, Curt Czajkowski, BS, MT(ASCP), Veronika Mladenova, BS, Stefanie Dugan, MS, CGC, Valerie Trapp-Stamborski, PhD, Kenneth D Friedman, MD, Rupa A Udani, PhD

Blood (2016) 128 (22): 1361.

https://doi.org/10.1182/blood.V128.22.1361.1361

Published: 2016

Journal Articles

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

Sandra L Haberichter, PhD, Tricia L Slobodianuk, Andrew Podd, Kenneth D Friedman, MD, Veronica H Flood, MD

Blood (2015) 126 (23): 1090.

https://doi.org/10.1182/blood.V126.23.1090.1090

Published: 2015

Journal Articles

Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form

Jessica A Lake, MD MPH, Kenneth D Friedman, MD, Veronica H Flood, MD, Shawn M Jobe, MD PhD, Rowena Punzalan, MD, Joan Cox Gill, MD

Blood (2015) 126 (23): 1052.

https://doi.org/10.1182/blood.V126.23.1052.1052

Published: 2015

Journal Articles

Genetic Evaluation in aHUS: Characterization of a Variant of Unknown Significance in CFHR3

Valerie Trapp-Stamborski, PhD, Stefanie N Dugan, MS, CGC, Kenneth D Friedman, MD, Matthew Anderson, MD, Rupa A Udani, PhD

Blood (2015) 126 (23): 1053.

https://doi.org/10.1182/blood.V126.23.1053.1053

Published: 2015

Journal Articles

Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program

Pamela A Christopherson, Veronica H Flood, MD, Sandra L Haberichter, PhD, Daniel B Bellissimo, PhD, Kenneth D Friedman, MD, Joan Cox Gill, MD, Rupa A Udani, PhD, Robert R Montgomery, MD

Blood (2015) 126 (23): 758.

https://doi.org/10.1182/blood.V126.23.758.758

Published: 2015

Journal Articles

Spectrum of Type 2 Von Willebrand Disease in the Zimmerman Program

Veronica H Flood, MD, Pamela A Christopherson, Daniel B Bellissimo, PhD, Joan Cox Gill, MD, Sandra L Haberichter, PhD, Kenneth D Friedman, MD, Rupa A Udani, PhD, Jonathan C Roberts, Robert R Montgomery, MD, The Zimmerman Program Investigators

Blood (2014) 124 (21): 472.

https://doi.org/10.1182/blood.V124.21.472.472

Published: 2014

Journal Articles

Phenotypic Variability in Carriers of Von Willebrand Factor Truncating Sequence Variants in the Zimmerman Program

Daniel B Bellissimo, PhD, Rupa A Udani, PhD, Pamela A. Christopherson, Kenneth D. Friedman, MD, Joan Cox Gill, MD, Sandra L. Haberichter, PhD, Robert R Montgomery, MD, Veronica H. Flood, MD

Blood (2014) 124 (21): 2833.

https://doi.org/10.1182/blood.V124.21.2833.2833

Published: 2014

Journal Articles

A Retrospective Analysis of Bleeding Phenotype and Von Willebrand Factor Exon 28 Polymorphism D1472H at a Single Institution

Kristina M. Haley, DO, Kenneth D. Friedman, MD, Michael Recht, MD PhD

Blood (2014) 124 (21): 2849.

https://doi.org/10.1182/blood.V124.21.2849.2849

Published: 2014

Journal Articles

The Management of Bleeding Risk in Von Willebrand Disease: Should Blood Group O Make a Difference?

Joan Cox Gill, MD, Veronica H Flood, MD, Pamela A Christopherson, Daniel B Bellissimo, PhD, Kenneth D Friedman, MD, Sandra L Haberichter, PhD, Rupa A Udani, PhD, Robert R. Montgomery, MD, The Zimmerman Program Investigators

Blood (2014) 124 (21): 2829.

https://doi.org/10.1182/blood.V124.21.2829.2829

Published: 2014

Journal Articles

Development and Validation of a Chromogenic Direct Thrombin Inhibitor Assay on the ACL Top 700 for Quantifying Dabigatran Levels in Plasma

Paula M Jacobi, Sharniece Covill, Andrew S Podd, PhD, Kenneth D Friedman, MD, Sandra L Haberichter, PhD

Blood (2014) 124 (21): 1548.

https://doi.org/10.1182/blood.V124.21.1548.1548

Published: 2014

Journal Articles

Impact of Age and Gender on Bleeding Score in Type 1 VWD Using the ISTH-BAT

Pamela A Christopherson, Veronica H Flood, MD, Kenneth D. Friedman, MD, Joan Cox Gill, MD, Sandra L Haberichter, PhD, Robert R Montgomery, MD, Thomas C. Abshire, MD, the Zimmerman Program Investigators

Blood (2014) 124 (21): 1510.

https://doi.org/10.1182/blood.V124.21.1510.1510

Published: 2014

Journal Articles

Binding Of VWF To Type IV Collagen: An Additional Collagen Binding Mechanism Beyond Types I, III, and VI Collagen?

Veronica H. Flood, MD, Joan Cox Gill, Sandra L. Haberichter, Daniel B Bellissimo, PhD, Pamela A Christopherson, Kenneth D Friedman, MD, Robert R. Montgomery, MD, The Zimmerman Program Investigators

Blood (2013) 122 (21): 333.

https://doi.org/10.1182/blood.V122.21.333.333

Published: 2013

Journal Articles

Patients with Bleeding Phenotype and Von Willebrand Exon 28 Polymorphism D1472H: A Retrospective Analysis At a Single Institution

Crawford A Jessica, MD, Jennifer E. Dietrich, MD, MSc, Shui-Ki Rocki Hui, MD, Kenneth D Friedman, MD, Donald Mahoney, Jr., MD, Venkateswaran Lakshmi, MD

Blood (2012) 120 (21): 100.

https://doi.org/10.1182/blood.V120.21.100.100

Published: 2012

Journal Articles

Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease

Veronica H Flood, MD, Joan Cox Gill, MD, Kenneth D Friedman, MD, Pamela A Christopherson, Paula M. Jacobi, BS, Robert R. Montgomery, MD, Sandra L Haberichter, PhD

Blood (2011) 118 (21): 379.

https://doi.org/10.1182/blood.V118.21.379.379

Published: 2011

Journal Articles

Quantitative Analysis of VWF Multimer Structure: Discrimination Between VWD Subtypes

Sandra L Haberichter, PhD, Paula M Jacobi, BA, Veronica H Flood, MD, Pamela A. Christopherson, Joan Cox Gill, MD, Daniel B. Bellissimo, PhD, Kenneth D Friedman, MD, The Zimmerman Program Investigators

Blood (2011) 118 (21): 1215.

https://doi.org/10.1182/blood.V118.21.1215.1215

Published: 2011

Journal Articles

Fourteen Percent of Healthy African Americans Participating In the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB VWD) Are Heterozygous for the VWF Gene Mutation H817Q Associated with Type 2N Von Willebrand Disease

Kenneth D Friedman, MD, Daniel B. Bellissimo, PhD, Pamela A. Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Robert R. Montgomery, MD, Sandra L Haberichter, PhD, Primary Clinical Center Directors

Blood (2010) 116 (21): 239.

https://doi.org/10.1182/blood.V116.21.239.239

Published: 2010

NARROW

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form

Genetic Evaluation in aHUS: Characterization of a Variant of Unknown Significance in CFHR3

Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program

Spectrum of Type 2 Von Willebrand Disease in the Zimmerman Program

Phenotypic Variability in Carriers of Von Willebrand Factor Truncating Sequence Variants in the Zimmerman Program

A Retrospective Analysis of Bleeding Phenotype and Von Willebrand Factor Exon 28 Polymorphism D1472H at a Single Institution

The Management of Bleeding Risk in Von Willebrand Disease: Should Blood Group O Make a Difference?

Development and Validation of a Chromogenic Direct Thrombin Inhibitor Assay on the ACL Top 700 for Quantifying Dabigatran Levels in Plasma

Impact of Age and Gender on Bleeding Score in Type 1 VWD Using the ISTH-BAT

Binding Of VWF To Type IV Collagen: An Additional Collagen Binding Mechanism Beyond Types I, III, and VI Collagen?

Patients with Bleeding Phenotype and Von Willebrand Exon 28 Polymorphism D1472H: A Retrospective Analysis At a Single Institution

Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease

Quantitative Analysis of VWF Multimer Structure: Discrimination Between VWD Subtypes

Fourteen Percent of Healthy African Americans Participating In the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB VWD) Are Heterozygous for the VWF Gene Mutation H817Q Associated with Type 2N Von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only